Aandeel SGBCF SHANGHAI HENLIUS BIOTECH, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Shanghai Henlius Biotech, Inc. OTC Markets

Aandelen

SGBCF

CNE100003N76

Beurs gesloten - OTC Markets
Andere beurzen
 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
- USD -.--% Intraday-grafiek van Shanghai Henlius Biotech, Inc. -.--% -.--%
14/05 Shanghai Henlius Biotech krijgt groen licht voor klinische proeven van medicijn tegen borstkanker in China MT
14/05 Shanghai Henlius Biotech, Inc. kondigt aan dat de National Medical Products Administration de aanvraag voor klinische proeven met HLX78 (lasofoxifeen) heeft goedgekeurd CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Shanghai Henlius Biotech Gets Go-Ahead for Clinical Trials of Breast Cancer Drug in China
Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration
Henlius Biotech Gets US FDA Clearance for Phase 3 Trial of Gastric Cancer Combination Therapy
Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration
Henlius Biotech Logs 1.35 Billion Yuan Revenue in Q1
Henlius maintained a positive momentum of development in Q1 2024, with impressive performances by core products
Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA
Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China
Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China
Shanghai Henlius Biotech, Inc. - IND Application for the Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein HLX53 in Combination with HANSIZHUANG Plus HANBEITAI Approved by NMPA
Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity
Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint
Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® Biosimilar Candidate HLX14 Met Primary Endpoints
Phase 3 Trial of Shanghai Henlius Biotech’s Osteoporosis Drug Meets Primary Study Endpoints
Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints
Shanghai Henlius Biotech Turns to Profit in 2023
Shanghai Henlius Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers 2696
  4. Koers SGBCF
  5. Nieuws Shanghai Henlius Biotech, Inc.
  6. Andere talen